查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2040947

炭疽菌疫苗市場預測至2034年—按疫苗類型、疾病、年齡層、應用、最終用戶和地區分類的全球分析

Anthrax Vaccine Market Forecasts to 2034 - Global Analysis By Vaccine Type (Live Attenuated Vaccine, Cell Free PA Vaccine and Other Vaccine Types), Type, Disease Indication, Age Group, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球炭疽菌疫苗市場規模將達到 155.8 億美元，並在預測期內以 6.5% 的複合年成長率成長，到 2034 年將達到 258 億美元。

炭疽菌疫苗是預防炭疽感染的措施，炭疽是由炭疽菌桿菌引起的嚴重細菌感染疾病。炭疽可感染人類和其他動物，其感染途徑有三種：皮膚型、吸入型和胃腸道型。該疫苗最初研發的目的是保護相關人員、實驗室工作人員以及其他高風險接觸炭疽菌的人。疫苗透過刺激免疫系統產生針對炭疽菌桿菌保護性抗原成分的抗體來發揮作用。

根據2021年4月發表在《獸醫世界雜誌》上的一篇論文，使用固定效應模型對2452個檢體進行分析顯示，全球炭疽病患病率為28%。使用隨機效應模型按洲進行亞組分析顯示，炭疽病綜合盛行率在非洲最高（29%），在北美洲最低（21%）。

炭疽病患病率增加

炭疽疫苗的盛行率顯著上升，反映出人們對炭疽風險的日益關注。這一上升趨勢增加了對有效疫苗的需求，並推動了研發的進步。炭疽流行率的上升凸顯了製定全面疫苗接種策略的必要性，從而推動了市場成長和創新。然而，對公眾健康而言，最重要的是提高大眾對炭疽疫苗的認知和教育，這也是市場成長的促進因素。

副作用和安全問題

炭疽菌疫苗雖然能有效預防炭疽菌，但可能引起輕度至中度的副作用，例如注射部位疼痛、腫脹和發紅。部分患者可能出現發燒、肌肉疼痛或疲勞。嚴重的過敏反應雖然罕見，但也可能發生。安全方面的擔憂包括不利事件的報告，但總體而言，其風險效益比支持在炭疽菌暴露高風險族群中使用。這些因素正在阻礙市場成長。

技術進步

市場正經歷顯著的技術進步，包括採用創新遞送系統和佐劑以提高有效性和安全性的新一代疫苗的研發。重組DNA技術等先進生物技術正被用於生產更有效、更容易大規模生產的疫苗。此外，製劑和儲存技術的進步也圖了疫苗的穩定性並促進了疫苗的分發。

高昂的製造成本

複雜的生產流程、嚴格的品管措施以及對專用設施的需求導致了高昂的成本。這些高昂的生產成本不僅影響疫苗的可負擔性，也為市場准入和廣泛分發帶來挑戰，限制了更多人群獲得疫苗。解決這些成本相關的障礙對於提高炭疽菌疫苗的可負擔性和可近性至關重要。這些因素正在阻礙市場成長。

新冠疫情的影響：

新冠疫情透過改變醫療保健的優先事項和資源配置，間接影響了炭疽疫苗市場。疫情因應所投入的關注和經費可能延緩了炭疽菌疫苗的研發。此外，供應鏈和醫療保健系統的中斷也可能影響疫苗的生產和分銷。然而，公眾對公共衛生和生物防禦的高度關注凸顯了炭疽菌疫苗的重要性，這可能會在疫情後時期促使人們更加關注並加強對炭疽疫苗的投資。

在預測期內，減毒活疫苗細分市場預計將成為最大的細分市場。

在預測期內，活病毒疫苗細分市場預計將佔據最大佔有率。炭疽菌活病毒疫苗作為一種極具前景的免疫接種方法，正日益受到市場關注。這些疫苗利用減毒炭疽菌誘發強烈的免疫反應，而不會引發疾病。在炭疽菌疫苗市場，由於活病毒疫苗能夠有效提供長期免疫力，其需求正在顯著增加。

在預測期內，藥房行業預計將呈現最高的複合年成長率。

在預測期內，藥局通路預計將呈現最高的複合年成長率。這些機構是炭疽菌疫苗的供應中心，確保個人和醫護人員能夠方便取得所需的疫苗。藥房還透過提供有關疫苗接種計劃、潛在副作用和正確接種方法的資訊和指導，為公共衛生做出貢獻。藥局參與炭疽菌疫苗市場有助於提高疫苗的整體供應量，並促進社區對這種嚴重感染疾病的保護。

市佔率最大的地區：

預計北美將在預測期內佔據最大的市場佔有率。該地區完善的醫療保健基礎設施以及人們對生物恐怖主義威脅日益增強的認知，正推動市場擴張。主要市場參與者正積極進行研發工作，以提高疫苗的有效性，進而增強市場競爭力。此外，製藥公司與政府機構之間的策略合作也進一步促進了市場動態，確保炭疽菌疫苗的需求穩定成長。

複合年成長率最高的地區：

預計亞太地區在預測期內將維持最高的複合年成長率。各國政府大力推廣疫苗接種，加上醫療基礎設施的進步，正在推動市場擴張。該地區的領先企業正致力於研發，以提高疫苗的有效性。日益重視公共衛生措施和應對生物恐怖攻擊的準備工作，進一步刺激了該地區對炭疽菌疫苗的需求。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球炭疽菌疫苗市場：依疫苗類型分類

  • 減毒活疫苗
  • 無細胞PA疫苗
    • 可吸收炭疽疫苗（AVA）
    • 沉澱炭疽疫苗（AVP）
  • 其他疫苗類型

第6章 全球炭疽菌疫苗市場：依類型分類

  • 次單位疫苗
    • 類毒素疫苗
    • 結合疫苗
    • 重組疫苗
  • 病毒載體疫苗
  • 其他類型

第7章 全球炭疽菌疫苗市場：依適應症分類

  • 病毒性疾病
    • 流感
    • 肝炎
    • 帶狀皰疹
    • 輪狀病毒
    • 其他病毒性疾病
  • 細菌疫苗
    • 肺炎鏈球菌感染
    • 病菌感染
    • 細菌疫苗
  • 其他跡象

第8章 全球炭疽菌疫苗市場：依年齡層別分類

  • 成人
  • 兒童

第9章 全球炭疽菌疫苗市場：依應用分類

  • 對人類而言
  • 動物
  • 其他用途

第10章 全球炭疽菌疫苗市場：依最終用戶分類

  • 藥局
  • 醫院
  • 其他最終用戶

第11章 全球炭疽菌疫苗市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第12章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第13章：公司簡介

  • AstraZeneca
  • BioNTech SE
  • Colondo Serum Company
  • Emergent Bio Solutions
  • Merck & Co., Inc
  • Moderna Inc.
  • Pfizer Inc
  • Proton Biopharma Ltd
  • Sanofi
  • Seqirus
  • Serum Institute of India Pvt. Ltd
  • ICON plc
Product Code: SMRC25161

According to Stratistics MRC, the Global Anthrax Vaccine Market is accounted for $15.58 billion in 2026 and is expected to reach $25.80 billion by 2034 growing at a CAGR of 6.5% during the forecast period. The Anthrax vaccine is a preventive measure designed to protect individuals from anthrax, a potentially serious bacterial infection caused by the bacterium Bacillus anthracis. Anthrax can affect humans and other animals, and it can occur in three forms: cutaneous (skin), inhalation, and gastrointestinal. The vaccine is primarily developed to safeguard military personnel, laboratory workers, and individuals at high risk of exposure to anthrax spores. The vaccine stimulates the immune system to produce antibodies against the protective antigen component of the bacillus anthracis bacterium.

According to an article published in the Veterinary World Journal in April 2021, the prevalence of anthrax globally was 28% from 2452 samples through the fixed effects model. The random effects model's continent-by-subgroup study showed that the pooled prevalence of anthrax was highest in Africa (29%) and lowest in North America (21%).

Market Dynamics:

Driver:

Increase in prevalence of anthrax

The market has witnessed a notable surge in prevalence, reflecting a growing concern for anthrax-related risks. This upswing has heightened demand for effective vaccines, prompting advancements in research and development. The increasing prevalence of anthrax underscores the imperative for comprehensive vaccination strategies, driving market growth and innovation. However, increasing awareness and education about anthrax vaccines is paramount for public health is the factor propelling the growth of the market.

Restraint:

Side effects and safety concerns

The anthrax vaccine, while effective in preventing anthrax, may cause mild to moderate side effects such as pain, swelling, or redness at the injection site. Some individuals may experience fever, muscle aches, or fatigue. Severe allergic reactions are rare but possible. Safety concerns include reports of adverse events, though the overall risk-benefit profile supports its use for those at high risk of anthrax exposure. These are the factors hampering the growth of the market.

Opportunity:

Technological advancements

The market has witnessed significant technological advancements, with the development of next-generation vaccines incorporating innovative delivery systems and adjuvant to enhance efficacy and safety. Advanced biotechnological methods, such as recombinant DNA technology, have been employed to produce more effective and scalable vaccines. Additionally, advancements in formulation and storage technologies contribute to improved stability and ease of distribution.

Threat:

High manufacturing costs

The complex production process, stringent quality control measures, and the need for specialized facilities contribute to elevated expenses. These high manufacturing costs not only impact the affordability of the vaccine but also pose challenges for market accessibility and widespread distribution, limiting its availability to a broader population. Addressing these cost-related barriers is crucial for enhancing the affordability and accessibility of anthrax vaccines. These are the factors hindering the growth of the market.

Covid-19 Impact:

The COVID-19 pandemic has indirectly impacted the market, with shifts in healthcare priorities and resources. Attention and funding diverted to combat the pandemic may have slowed Anthrax vaccine research and development. Additionally, disruptions in supply chains and healthcare systems could affect manufacturing and distribution. However, the heightened focus on public health and biodefense may underscore the importance of anthrax vaccines, potentially leading to increased awareness and investment in the post-pandemic landscape.

The live attenuated vaccine segment is expected to be the largest during the forecast period

The live attenuated vaccine segment is expected to be the largest during the forecast period. Live attenuated vaccines for anthrax have gained prominence in the market, offering a promising approach to immunization. Leveraging weakened forms of the anthrax bacterium, these vaccines stimulate a robust immune response without causing the disease. The market for anthrax vaccines is witnessing a notable surge in demand for live attenuated options due to their efficacy in conferring long-lasting immunity.

The pharmacies segment is expected to have the highest CAGR during the forecast period

The pharmacies segment is expected to have the highest CAGR during the forecast period. These establishments serve as distribution points for anthrax vaccines, ensuring that individuals and healthcare providers can easily procure the necessary doses. Pharmacies also contribute to public health by offering information and guidance on vaccination schedules, potential side effects, and proper administration. Their involvement in the Anthrax Vaccine market enhances overall vaccine availability and promotes community protection against this serious infectious disease.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. The region's robust healthcare infrastructure and rising awareness regarding bioterrorism threats contribute to market expansion. Key market players are actively engaged in research and development to enhance vaccine efficacy, fostering market competitiveness. Additionally, strategic collaborations between pharmaceutical companies and government bodies further propel market dynamics, ensuring a steady surge in demand for anthrax vaccines.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. Government initiatives promoting vaccination, coupled with advancements in healthcare infrastructure, contribute to market expansion. Key players in the region are focusing on research and development to enhance vaccine efficacy. The growing emphasis on public health measures and preparedness against bioterrorism incidents further propels the demand for anthrax vaccines in the region.

Key players in the market

Some of the key players in Anthrax Vaccine market include AstraZeneca, BioNTech SE, Colondo Serum Company, Emergent Bio Solutions, Merck & Co., Inc, Moderna Inc., Pfizer Inc, Proton Biopharma Ltd, Sanofi, Seqirus, Serum Institute of India Pvt. Ltd and ICON plc.

Key Developments:

In October 2022, ICON plc was selected by the US Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the Department of Health and Human Services (HHS), to execute an anthrax vaccine clinical trial. The Anthrax vaccine AV7909 is currently under clinical trial evaluation.

In June 2022, Emergent BioSolutions Inc. was granted review acceptance of the Biologics License Application (BLA) for AV7909 (Anthrax Vaccine Adsorbed, Adjuvanted) from the US FDA. AV7909 is evaluated for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in adults (age group 18 - 65). The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is in April 2023.

Vaccine Types Covered:

  • Live Attenuated Vaccine
  • Cell Free PA Vaccine
  • Other Vaccine Types

Types Covered:

  • Subunit Vaccines
  • Viral Vector Vaccines
  • Other Types

Disease Indications Covered:

  • Viral Disease
  • Bacterial Vaccine
  • Other Disease Indications

Age Groups Covered:

  • Adult
  • Pediatric

Applications Covered:

  • Human Use
  • Animal Use
  • Other Applications

End Users Covered:

  • Pharmacies
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Anthrax Vaccine Market, By Vaccine Type

  • 5.1 Introduction
  • 5.2 Live Attenuated Vaccine
  • 5.3 Cell Free PA Vaccine
    • 5.3.1 Anthrax Vaccine Absorbed (AVA)
    • 5.3.2 Anthrax Vaccine Precipitated (AVP)
  • 5.4 Other Vaccine Types

6 Global Anthrax Vaccine Market, By Type

  • 6.1 Introduction
  • 6.2 Subunit Vaccines
    • 6.2.1 Toxoid Vaccines
    • 6.2.2 Conjugate Vaccines
    • 6.2.3 Recombinant vaccines
  • 6.3 Viral Vector Vaccines
  • 6.4 Other Types

7 Global Anthrax Vaccine Market, By Disease Indication

  • 7.1 Introduction
  • 7.2 Viral Disease
    • 7.2.1 Influenza
    • 7.2.2 Hepatitis
    • 7.2.3 Herpes Zoster
    • 7.2.4 Rotavirus
    • 7.2.5 Other Viral Diseases
  • 7.3 Bacterial Vaccine
    • 7.3.1 Pneumococcal Diseases
    • 7.3.2 Meningococcal Diseases
    • 7.3.3 Bacterial Vaccines
  • 7.4 Other Disease Indications

8 Global Anthrax Vaccine Market, By Age Group

  • 8.1 Introduction
  • 8.2 Adult
  • 8.3 Pediatric

9 Global Anthrax Vaccine Market, By Application

  • 9.1 Introduction
  • 9.2 Human Use
  • 9.3 Animal Use
  • 9.4 Other Applications

10 Global Anthrax Vaccine Market, By End User

  • 10.1 Introduction
  • 10.2 Pharmacies
  • 10.3 Hospitals
  • 10.4 Other End Users

11 Global Anthrax Vaccine Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 AstraZeneca
  • 13.2 BioNTech SE
  • 13.3 Colondo Serum Company
  • 13.4 Emergent Bio Solutions
  • 13.5 Merck & Co., Inc
  • 13.6 Moderna Inc.
  • 13.7 Pfizer Inc
  • 13.8 Proton Biopharma Ltd
  • 13.9 Sanofi
  • 13.10 Seqirus
  • 13.11 Serum Institute of India Pvt. Ltd
  • 13.12 ICON plc

List of Tables

  • Table 1 Global Anthrax Vaccine Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Anthrax Vaccine Market Outlook, By Vaccine Type (2023-2034) ($MN)
  • Table 3 Global Anthrax Vaccine Market Outlook, By Live Attenuated Vaccine (2023-2034) ($MN)
  • Table 4 Global Anthrax Vaccine Market Outlook, By Cell Free PA Vaccine (2023-2034) ($MN)
  • Table 5 Global Anthrax Vaccine Market Outlook, By Anthrax Vaccine Absorbed (AVA) (2023-2034) ($MN)
  • Table 6 Global Anthrax Vaccine Market Outlook, By Anthrax Vaccine Precipitated (AVP) (2023-2034) ($MN)
  • Table 7 Global Anthrax Vaccine Market Outlook, By Other Vaccine Types (2023-2034) ($MN)
  • Table 8 Global Anthrax Vaccine Market Outlook, By Type (2023-2034) ($MN)
  • Table 9 Global Anthrax Vaccine Market Outlook, By Subunit Vaccines (2023-2034) ($MN)
  • Table 10 Global Anthrax Vaccine Market Outlook, By Toxoid Vaccines (2023-2034) ($MN)
  • Table 11 Global Anthrax Vaccine Market Outlook, By Conjugate Vaccines (2023-2034) ($MN)
  • Table 12 Global Anthrax Vaccine Market Outlook, By Recombinant vaccines (2023-2034) ($MN)
  • Table 13 Global Anthrax Vaccine Market Outlook, By Viral Vector Vaccines (2023-2034) ($MN)
  • Table 14 Global Anthrax Vaccine Market Outlook, By Other Types (2023-2034) ($MN)
  • Table 15 Global Anthrax Vaccine Market Outlook, By Disease Indication (2023-2034) ($MN)
  • Table 16 Global Anthrax Vaccine Market Outlook, By Viral Disease (2023-2034) ($MN)
  • Table 17 Global Anthrax Vaccine Market Outlook, By Influenza (2023-2034) ($MN)
  • Table 18 Global Anthrax Vaccine Market Outlook, By Hepatitis (2023-2034) ($MN)
  • Table 19 Global Anthrax Vaccine Market Outlook, By Herpes Zoster (2023-2034) ($MN)
  • Table 20 Global Anthrax Vaccine Market Outlook, By Rotavirus (2023-2034) ($MN)
  • Table 21 Global Anthrax Vaccine Market Outlook, By Other Viral Diseases (2023-2034) ($MN)
  • Table 22 Global Anthrax Vaccine Market Outlook, By Bacterial Vaccine (2023-2034) ($MN)
  • Table 23 Global Anthrax Vaccine Market Outlook, By Pneumococcal Diseases (2023-2034) ($MN)
  • Table 24 Global Anthrax Vaccine Market Outlook, By Meningococcal Diseases (2023-2034) ($MN)
  • Table 25 Global Anthrax Vaccine Market Outlook, By Bacterial Vaccines (2023-2034) ($MN)
  • Table 26 Global Anthrax Vaccine Market Outlook, By Other Disease Indications (2023-2034) ($MN)
  • Table 27 Global Anthrax Vaccine Market Outlook, By Age Group (2023-2034) ($MN)
  • Table 28 Global Anthrax Vaccine Market Outlook, By Adult (2023-2034) ($MN)
  • Table 29 Global Anthrax Vaccine Market Outlook, By Pediatric (2023-2034) ($MN)
  • Table 30 Global Anthrax Vaccine Market Outlook, By Application (2023-2034) ($MN)
  • Table 31 Global Anthrax Vaccine Market Outlook, By Human Use (2023-2034) ($MN)
  • Table 32 Global Anthrax Vaccine Market Outlook, By Animal Use (2023-2034) ($MN)
  • Table 33 Global Anthrax Vaccine Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 34 Global Anthrax Vaccine Market Outlook, By End User (2023-2034) ($MN)
  • Table 35 Global Anthrax Vaccine Market Outlook, By Pharmacies (2023-2034) ($MN)
  • Table 36 Global Anthrax Vaccine Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 37 Global Anthrax Vaccine Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.